Cytokinetics’ Failure In ALS Clears Way For Focus On Aficamten

 
• By Joseph Haas
  
change of focus
With its ALS program shuttered, Cytokinetics will put all focus on aficamten • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D